← back to search

Andrew B. Sharabi

UC San Diego Health System · US
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Head and Neck Cancer Studies, and Cancer Genomics and Diagnostics.
h-index
36
citations
6,570
works
247
NIH funding
primary concept
email

Recent publications

The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy
Nature Communications 2025cited by 12position: middledoi
CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma
Frontiers in Immunology 2025cited by 10position: middledoi
Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway
Cell Reports 2023cited by 52position: lastdoi
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
Nature Communications 2022cited by 163position: middledoi
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Pharmacology & Therapeutics 2022cited by 128position: lastdoi
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
Nature Communications 2022cited by 62position: middledoi
Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs
Molecular Cancer Therapeutics 2022cited by 44position: middledoi
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety
Cancer 2021cited by 69position: middledoi
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Nature Communications 2020cited by 298position: middledoi
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Clinical Cancer Research 2020cited by 203position: lastdoi
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Molecular Cancer Therapeutics 2020cited by 101position: middledoi
Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer
Seminars in Radiation Oncology 2020cited by 82position: middledoi
Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Clinical Cancer Research 2020cited by 75position: middledoi
Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation
International Journal of Radiation Oncology*Biology*Physics 2020cited by 47position: middledoi
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Nature Communications 2019cited by 170position: middledoi
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
Clinical Cancer Research 2019cited by 162position: lastdoi
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer
Cancer Research 2019cited by 74position: lastdoi
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Clinical Cancer Research 2018cited by 318position: middledoi
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
Cancer Immunology Research 2018cited by 83position: middledoi
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Clinical Cancer Research 2017cited by 847position: middledoi
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
The Oncologist 2017cited by 110position: firstdoi
Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans
The Annals of Thoracic Surgery 2017cited by 71position: middledoi
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
The Lancet Oncology 2015cited by 883position: firstdoi
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Cancer Immunology Research 2014cited by 643position: firstdoi
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Journal for ImmunoTherapy of Cancer 2014cited by 140position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

J. Silvio Gutkind · University of San Diego9 papers (2019–2025)Ezra E.W. Cohen · University of Michigan7 papers (2019–2023)Charles G. Drake · Johnson & Johnson (United States)5 papers (2014–2018)Sayuri Miyauchi · UC San Diego Health System5 papers (2019–2025)Sangwoo S. Kim · University of California San Diego5 papers (2017–2023)Loren K. Mell · Johns Hopkins Medicine5 papers (2019–2021)Shumei Kato · UC San Diego Health System4 papers (2017–2020)Zhiyong Wang · University of San Diego4 papers (2019–2022)Robert Saddawi‐Konefka · The University of Texas MD Anderson Cancer Center4 papers (2022–2025)Ida Franiak‐Pietryga · National Foundation for Cancer Research4 papers (2020–2025)Michael M. Allevato · University of California San Diego4 papers (2019–2025)Razelle Kurzrock · Froedtert Hospital4 papers (2017–2020)Alfredo Molinolo · McGill University3 papers (2019–2022)Riyam Al Msari · National Foundation for Cancer Research3 papers (2022–2025)Aaron M. Goodman · Moores Cancer Center3 papers (2017–2020)Theodore L. DeWeese · Brady (Norway)3 papers (2014–2018)Bryan S. Yung · UC San Diego Health System3 papers (2019–2025)Victoria H. Wu · University School3 papers (2019–2022)P. Dominick Sanders · University of California San Diego3 papers (2017–2020)Brian J. Francica · Energy Biosciences Institute3 papers (2014–2018)